Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tropocells is an Israeli regenerative medicine company specializing in advanced Platelet-Rich Plasma (PRP) preparation systems. Founded by serial entrepreneur Dr. Shimon Eckhouse, the company provides a proprietary gel-separator technology that allows for the rapid and efficient concentration of platelets and growth factors from a patient's own blood. Their products are primarily used in orthopedics for joint and tendon repair, as well as in medical aesthetics for skin rejuvenation and hair loss treatments. The Tropocells system is designed to minimize red blood cell and granulocyte contamination, enhancing the therapeutic profile of the resulting plasma. The technology is FDA-cleared and CE-marked, supporting its use in clinical practices worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tropocells.